A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Partial Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated Vasculitis

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BDB 001 Beijing Defengrei Biotechnology (Primary) ; Cyclophosphamide; Prednisone
Indications Granulomatosis with polyangiitis; Vasculitis
Focus Therapeutic Use
Sponsors Staidson Beijing BioPharmaceuticals

Most Recent Events

11 Oct 2023 Planned number of patients changed from 60 to 100.
11 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Mar 2025.
11 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Mar 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight